Minerva Neurosciences Inc Stock News

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Minerv...

Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy

BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-...

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Mi...